Most Read Articles
Audrey Abella, 03 Dec 2019
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab gains the upper hand over sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), according to the results of the phase III IMbrave150*** trial presented at ESMO Asia 2019.
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.

Liver fibrosis scores help predict poor outcomes in seniors

29 Aug 2019

Liver fibrosis scores aid in predicting the risk of poor health outcomes among elderly adults, a recent study has shown.

The study included 962 participants (mean age, 74.4±6.9 years; 55.5 percent female) who were followed for a mean of 95.7 months. Four liver fibrosis scores were assessed: fibrosis-4 (FIB-4), nonalcoholic fatty live disease (NAFLD) fibrosis score (NFS), aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT) and the BARD score.

A total of 330 deaths were reported, resulting in an overall rate of 34.4 percent. There were also 139 cases (14.9 percent) of cardiovascular (CV) disease, 74 (7.9 percent) of neoplasms and 25 (2.7 percent) of respiratory diseases.

Those at intermediate (hazard ratio [HR], 1.51, 95 percent CI, 1.16–1.96) and high (HR, 2.86, 2.12–3.85) risk of fibrosis, as evaluated by the FIB-4, were significantly more likely to die of all causes. The same was true for CV mortality (intermediate: HR, 1.96, 1.33–2.9; high: HR, 3.57, 2.27–5.62).

Participants in the intermediate (overall mortality: adjusted HR, 1.78, 1.29–2.47; CV mortality: adjusted HR, 2.9, 1.80–4.66) and high (overall mortality: adjusted HR, 1.6, 1.21–2.1; CV mortality: adjusted HR, 2.42, 1.61–3.64) risk classes, as determined by the NFS, were also significantly more likely to suffer from poor outcomes.

In comparison, both intermediate and high fibrosis risk categories, as classified by the AST/ALT ratio, were associated only with overall mortality. Outcome prediction according to BARD, on the other hand, was significant only for those categorized with high risk of fibrosis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Dec 2019
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab gains the upper hand over sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), according to the results of the phase III IMbrave150*** trial presented at ESMO Asia 2019.
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.